Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-label, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of [177Lu]Ludotadipep Treatment for Metastatic Castration-resistant Prostate Cancer

NCT07853209 is registered in ClinicalTrials.gov with FutureChem as lead sponsor.

NCT NCT07853209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07853209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-label, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of [177Lu]Ludotadipep Treatment for Metastatic Castration-resistant Prostate Cancer
Lead sponsor
FutureChem
Phase
Phase 3
Overall status
Recruiting
Start date
January 26, 2026
Completion date
January 26, 2029
Enrollment
114 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

mcrpc, prostate cancer